Market Overview

Lemelson Doubles Short Position In Ligand Pharmaceuticals, Says It's Created 'Pyramid Scheme Of Shell Companies'

Share:
Lemelson Doubles Short Position In Ligand Pharmaceuticals, Says It's Created 'Pyramid Scheme Of Shell Companies'
Related LGND
The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering
The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs
Healthcare And Biotechnology Dashboard - Update (Seeking Alpha)
Related VKTX
Viking Has A More Attractive M&A Valuation Than Madrigal, Raymond James Says In Upgrade
Benzinga's Top Upgrades, Downgrades For November 19, 2018
B. Riley FBR likes NASH players Viking Therapeutics and Galmed Pharma in premarket analyst action (Seeking Alpha)

Rev. Emmanuel Lemelson was recently a guest on #PreMarket Prep, a daily trading idea radio show hosted by Joel Elconin and Dennis Dick. 

Shares of Ligand Pharmaceuticals Inc. (NASDAQ: LGND) hit new 52-week highs of $94.94 on Friday after the company updated the impact from the Viking Therapeutics Inc (NASDAQ: VKTX) initial public offering.

Ligand said that it sees $28.2 million of non-operating income during the second quarter related to its "gain on deconsolidation" from the Viking IPO of which the firm showed a nearly 50 percent ownership stake. The company also adjusted its full year 2015 earnings per share guidance from $2.14 to $2.18 to a new range $3.45 to $3.50, which accounts for the IPO.

Lemelson Short

One hedge fund manager took the opportunity to add to his short position in Ligand on the news.

Reverend Emmanuel Lemelson of Lemelson Capital Management discussed why he doubled his short position on Thursday during Friday's Benzinga #Premarket Prep show.

In Lemelson's words, Ligand has created a "pyramid scheme of shell companies" by IPO-ing Viking that has "almost no prospect" of future revenue and earnings with no assets. In the future, he said, Ligand will be used as a case study into the "excesses of the stock market."

He continued that Viking is merely a "tenant in their building" with "a few people renting space," while underwriters are promoting the issue "like it's going out of fashion."

Lemelson argued that Ligand is using its ownership stake to boost its balance sheet with the profits from the IPO being recorded as earnings. Ligand won't record any losses in its P&L from Viking even though the company "is guaranteed" to show losses in the future, he added.

"That's extraordinary financial engineering," the hedge fund manager argued. "That really makes the Greece financial apparatus look like saints."

In his opinion, Lemelson concluded that the company isn't "building a real product or business" and is merely a company with 18 employees and a $2 billion market capitalization.

"That's the kind of thing you want to short. It's just not sustainable."

Lemelson's commentary on Ligand begins at the 1:37:20 mark below.

Posted-In: #PreMarketPrepAnalyst Color Biotech Short Ideas Exclusives Trading Ideas Interview General Best of Benzinga

 

Related Articles (LGND + VKTX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
MOSJP MorganDowngrades33.0
BACKeefe Bruyette & WoodsDowngrades29.0
AMTMorgan StanleyDowngrades170.0
EBAYMorgan StanleyDowngrades33.0
UNITMorgan StanleyDowngrades16.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

#PreMarket Prep For The Week Of June 8: No Summer Break From Markets With These NYSE Traders, Fund Mangers & Market Technicians

Berger: Why I Bought Bank Of America Shares This Week